Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Additional Locations, Minnesota Clinical Trials

A listing of Additional Locations, Minnesota clinical trials actively recruiting patient volunteers.

RESULTS

Found (42) clinical trials

A Study of CNSA-001 in Primary Tetrahydrobiopterin Deficient Patients With Hyperphenylalaninemia

Tetrahydrobiopterin (BH4) is an essential cofactor for phenylalanine hydroxylase, tyrosine hydroxylase, tryptophan hydroxylase, fatty acid glycerylether oxygenase, and nitric oxide (NO) synthase. Primary tetrahydrobiopterin deficiency (PBD) is caused by deficiency of GTP cyclohydrolase I (GTP-CH), 6-pyruvoyl-tetrahydropterin synthase (PTPS), or sepiapterin reductase (SR) that impairs the biosynthesis of tetrahydrobiopterin (BH4) or ...

Phase

2.38 miles

Learn More »

Topical QR-313 in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Due to Mutation(s) in Exon 73 of the COL7A1gene

This clinical trial will evaluate the safety and tolerability, proof of mechanism, systemic exposure and preliminary efficacy following topical application of QR-313 to subjects with confirmed RDEB with one or more pathogenic mutations in exon 73 in the COL7A1 gene. Up to two Target Wound Areas (TWAs) per subject will ...

Phase

2.38 miles

Learn More »

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

PRIMARY OBJECTIVES: I. To assess the safety and maximum tolerated dose (MTD) of the addition of lenalidomide to the R-ICE chemoimmunotherapy regimen (lenalidomide-rituximab-ifosfamide-carboplatin-etoposide [R2ICE]) for the treatment of primary-refractory/first-relapse B-cell lymphoma. (Phase I) II. To determine if the addition of lenalidomide (based on dose determination from phase I) to the ...

Phase

2.57 miles

Learn More »

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors Including Central Nervous System Tumors

Phase 1 of this study, utilizing a rolling 6 design, will be conducted to determine a maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), and to describe the toxicities of lenvatinib administered in combination with everolimus once daily to pediatric participants with recurrent/refractory solid tumors. Phase 2, utilizing ...

Phase

2.98 miles

Learn More »

CNDO-109-AANK for AML in First Complete Remission (CR1)

This is a multi-center, open-label, non-controlled, non-randomized dose-escalating Phase 1 clinical study designed to examine the safety of infusing escalating doses of CNDO-109-Activated Allogeneic Natural Killer Cells-(from a first or second degree relative), after a preparatory chemotherapy regimen, in adult patients with acute myeloid leukemia (AML) who are in their ...

Phase

2.98 miles

Learn More »

Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors

The purpose of this study is to test the safety and efficacy of an investigational drug called APS001F when given with flucytosine (5-FC) for treatment of solid tumors. APS001F is a recombinant Bifidobacterium longum (a live bacteria normally found in the digestive tract) that has been modified to produce an ...

Phase

2.98 miles

Learn More »

A Safety Tolerability and Efficacy Study of VC-02 Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness

The purpose of this trial is to test if VC-02 combination product can be implanted subcutaneously in subjects with Type 1 Diabetes and Hypoglycemia Unawareness and maintained safely for up to two years. It will also test if VC-02 is an effective treatment for these subjects.

Phase

2.98 miles

Learn More »

Study Designed to Assess the Safety Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis

Part 1 of this trial will enroll healthy volunteers into a single ascending dose (SAD), multiple ascending dose (MAD), and Food Effect (FE) treatment groups. The SAD treatment group is comprised of at least 3 ascending dose level cohorts where healthy adult subjects will be randomized to receive a single ...

Phase

2.98 miles

Learn More »

Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma

Assessment of safety and tolerability of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) in advanced GI malignancies.

Phase

2.98 miles

Learn More »

Study to Investigate Safety Pharmacokinetic (PK) Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

This is a 4-part (Part A, Part B, Part C and Part D), Phase I/IIa, multi-center, open label, study in pediatric subjects with refractory or recurrent tumors. Part A is a repeat dose, dose escalation monotherapy study that will identify the recommended phase II dose (RP2D) on the continuous dosing ...

Phase

2.98 miles

Learn More »